These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 3002621)

  • 1. Contributions of nitrosoureas to cancer treatment.
    Mitchell EP; Schein PS
    Cancer Treat Rep; 1986 Jan; 70(1):31-41. PubMed ID: 3002621
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems.
    Johnston TP; Montgomery JA
    Cancer Treat Rep; 1986 Jan; 70(1):13-30. PubMed ID: 2935250
    [No Abstract]   [Full Text] [Related]  

  • 3. 3-(Tetraacetyl glucopyranos-2-yl)-1-(2-chloroethyl)-1-nitrosourea, an antitumor agent with modified bone marrow toxicity.
    Schein PS; McMenamin MG; Anderson T
    Cancer Res; 1973 Sep; 33(9):2005-9. PubMed ID: 4353476
    [No Abstract]   [Full Text] [Related]  

  • 4. Structure-activity studies of methylnitrosourea antitumor agents with reduced murine bone marrow toxicity.
    Panasci LC; Fox PA; Schein PS
    Cancer Res; 1977 Sep; 37(9):3321-8. PubMed ID: 141978
    [No Abstract]   [Full Text] [Related]  

  • 5. Biological and biochemical properties of 1-(2-chloroethyl)-3-(beta-D-glucopyranosyl)-1-nitrosourea (NSC D 254157), a nitrosourea with reduced bone marrow toxicity.
    Fox PA; Panasci LC; Schein PS
    Cancer Res; 1977 Mar; 37(3):783-7. PubMed ID: 138478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas.
    Wheeler GP; Bowdon BJ; Grimsley JA; Lloyd HH
    Cancer Res; 1974 Jan; 34(1):194-200. PubMed ID: 4809457
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas.
    Ali-Osman F; Giblin J; Berger M; Murphy MJ; Rosenblum ML
    Cancer Res; 1985 Sep; 45(9):4185-91. PubMed ID: 2411398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of chlorozotocin Nsc-178248), a new nitrosourea antitumor agent.
    Schein PS; Panasci L; Woolley PV; Anderson T
    Cancer Treat Rep; 1976 Jun; 60(6):801-5. PubMed ID: 133756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice.
    Panasci LC; Green D; Schein PS
    J Clin Invest; 1979 Oct; 64(4):1103-11. PubMed ID: 158033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas].
    Wakui A
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1327-38. PubMed ID: 6223595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of mechanism of action studies of the nitrosoureas.
    Bono VH
    Cancer Treat Rep; 1976 Jun; 60(6):699-702. PubMed ID: 182364
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of mutagenicity, antitumor activity, and chemical properties of selected nitrosoureas and nitrosoamides.
    Brundrett RB; Colvin M; White EH; McKee J; Hartman PE; Brown DL
    Cancer Res; 1979 Apr; 39(4):1328-33. PubMed ID: 421216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the biological and biochemical properties of 1-(4-amino-2-methylpyrimidin-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea and 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose.
    Nagourney RA; Fox P; Schein PS
    Cancer Res; 1978 Jan; 38(1):65-8. PubMed ID: 145314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Historical development and future promise of the nitrosoureas as anticancer agents.
    Schabel FM
    Cancer Chemother Rep 3; 1973 May; 4(3):3-6. PubMed ID: 4584035
    [No Abstract]   [Full Text] [Related]  

  • 15. Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose, an antitumor agent with modified bone marrow toxicity.
    Anderson T; McMenamin MG; Schein PS
    Cancer Res; 1975 Mar; 35(3):761-5. PubMed ID: 123170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships: nitrosoureas.
    Johnston TP
    Cancer Chemother Rep 3; 1972 May; 3(1):50-1. PubMed ID: 5065660
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of derivatives of Ara-C, 5-fluorouracil and nitrosourea against intracerebral implanted L1210 leukemia].
    Kato T; Ota K
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):502-5. PubMed ID: 2949703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo study of acute hematotoxicity of three nitrosoureas, chlorozotocin (chloro-2-ethyl)-ribofuranosyl-3-nitrosourea, and (chloro-2-ethyl)-1-ribopyranosyl-3-nitrosourea.
    Mori KJ; Jasmin C; Hayat M; MacDonald JS; Mathé G
    Cancer Res; 1980 Nov; 40(11):4282-6. PubMed ID: 6451285
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the experimental antitumor activities of three nitrosourea derivatives chlorozotocin, RFCNU and CNCC encapsulated in liposomes with those in the free state.
    Maral R; Bourut C; Chenu E; Mathe G; Bernon R; Lussan C; Imbach JL; Schein P; Bothorel P
    Oncology; 1985; 42(2):122-8. PubMed ID: 3157909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noval antitumor nitrosoureas and related compounds and their reactions with DNA.
    Lown JW; Joshua AV; McLaughlin LW
    J Med Chem; 1980 Jul; 23(7):798-805. PubMed ID: 7401107
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.